Nasopharyngeal Carcinoma Clinical Trial
Official title:
A Pilot Study to Evaluate the Use of a Transoral Flexible Endoscope With Magnifying Narrow Band Imaging in Nasopharyngeal Cancer
Nasopharyngeal carcinoma (NPC) is endemic in our region and is the 9th most common cancer in
Hong Kong. Traditionally diagnosis has been through a nasoendoscopic examination of the
nasopharynx with white light followed by a biopsy of suspicious lesions for a confirmatory
diagnosis. However, given the geometry of the anatomy of the nasopharynx, with its inherent
crevices and varying amounts of lymphoid tissues, lesions are not always easily identified
leading to potential missed lesions. The non-specific aspect of white light also leads to
excessive biopsies that are not without risk and of some discomfort to patients. Recent
advances in liquid biopsies have also allowed for the detection of earlier and smaller
lesions that are not always easily identified on nasoendoscopy but rather are seen on
Magnetic Resonance Imaging (MRI)1 .
An alternative imaging technique is the use of Narrow Band Imaging (NBI) to view the
vasculature of the mucosa to identify suspicious lesions for pre-malignancy and malignancy
that has been popularized in the gastrointestinal tract. In NPC, NBI with the flexible
nasoendoscopes has been used in the diagnosis of NPC with varying success2-5 . Our own
group's research has found that in NPC NBI has limitations arising from a lack of consensus
on vascular findings on NBI that constitute malignancy, lack of magnification and long focal
length of current nasoendoscopes5-8 . Flexible endoscopy using conventional
esophago-gastroscopy endoscope (OGD) with NBI and magnification power up to 80x overcome the
limitations of current nasoendoscopes, however their size precludes the passing of these
endoscopes through the nasal cavity.
Here in this pilot study we will seek to use an OGD with NBI passed transorally and
retroflexed into the nasopharynx to view the nasopharynx with increased magnification and
clarity to evaluate the feasibility of this study in the diagnosis of nasopharyngeal
carcinoma.
Study questions:
1. Is it feasible to use an OGD with magnifying NBI for the diagnosis of NPC?
2. Are there features detected on NBI OGD that are diagnostic of NPC?
3. Do histological features correspond with NBI findings?
This is a case-control pilot study. We will recruit 40 patients. 20 patients with newly
diagnosed primary NPC will be recruited to the test group. 20 patients undergoing an OGD for
lesions not involving disease of the head and neck region will be recruited to the control
group.
NBI OGD and flexible nasoendoscopy will be performed to examine patients' nasopharyngeal
region.
NBI OGD: Endoscopic procedures would be performed by our investigators with expertise on
performing upper endoscopy. Endoscopes with magnification and NBI function would be used
(GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached
to the tip of the endoscope for better focal length adjustment.
Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx
and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall
will be systematically examined with white light and NBI. Target suspicious areas would be
examined by use of magnification with the power up to 80X.
Flexible nasoendoscopy: The nasoendoscope is introduced into the nose, the nasal cavity and
nasopharyngnx. It has a camera and a light at the end and allows our doctor to check for any
abnormal looking areas. Upon identification of suspicious lesion. Biopsies of sites with
different NBI findings will be taken to correlate the NBI findings with histological
features.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05979961 -
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Recruiting |
NCT06055816 -
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05547971 -
Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
|
||
Not yet recruiting |
NCT05020925 -
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04547088 -
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04548271 -
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT02795169 -
Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02569788 -
Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02801487 -
Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT02237924 -
Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
|
Phase 2 | |
Recruiting |
NCT02044562 -
Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients
|
N/A | |
Terminated |
NCT01694576 -
NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation
|
Phase 2 | |
Recruiting |
NCT01462903 -
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
|
Phase 1 | |
Completed |
NCT01271439 -
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
|
Phase 2 | |
Completed |
NCT00535795 -
Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA
|
Phase 3 | |
Completed |
NCT00379262 -
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
|
Phase 3 | |
Completed |
NCT03398980 -
Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy
|
N/A | |
Completed |
NCT01309633 -
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
|
Phase 2 |